Processa completes $200 million acquisition of Vidya Therapeutics
Processa acquired Vidya Therapeutics and raised $200 million to advance its immunological and inflammatory disease pipeline, including VT-7208 into Phase 2 for conditions like food allergy.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed